Skip to main content
Toggle Nav
Cart() cart() cart(US $ 0.00)

New Labeling to Reflect Pregnancy Risks Associated with Antipsychotics


Get Your FREE Quote Instantly!
Get Started

New Labeling to Reflect Pregnancy Risks Associated with Antipsychotics

Antipsychotic medications will now bear new labeling in an effort to warn pregnant mothers about the drug risks that may impact their unborn babies if ingested. According to the U.S. Food and Drug Administration, certain drugs used to treat psychiatric disorders, including bipolar disorder and schizophrenia, put babies at risk for withdrawal symptoms.

The new labeling will reflect the risk for extrapyramidal signs, or abnormal muscle movement, as well as other withdrawal symptoms in newborn babies whose mothers took the medication in their third trimester of pregnancy, WebMD reported. Medications include Abilify, Clorazil, FazaClo, Fanapt, Geodon, Haldol and a slew of others.

However, the FDA warns that patients currently on these medications should not stop taking them without consulting a doctor first.

Withdrawal symptoms associated with these medications include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing and difficulty feeding. Some newborns' symptoms will subside within several hours or days and therefore won't require medical attention, but some may require longer hospital stays, the source reported.